Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 17/20 | 0.50 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | INSR | P06213 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982777 | 0.90 | AXL (0.53) | AXLKDRINSRMAP3K14 | |
| SCHEMBL929020 | 0.89 | AXL (0.49) | AXLKDRINSRNPC1PKM | |
| SCHEMBL4306108 | 0.89 | AXL (0.51) | AXLKDRINSRNPC1PKM | |
| SCHEMBL931041 | 0.87 | AXL (0.50) | AXLKDRINSRNPC1PKM | |
| SCHEMBL4988308 | 0.86 | AXL (0.52) | AXLKDRINSRNPC1PKM | |
| SCHEMBL4304418 | 0.84 | AXL (0.52) | AXLKDRINSRMAP3K14 | |
| SCHEMBL4305223 | 0.84 | AXL (0.54) | AXLKDRINSRMAP3K14 | |
| SCHEMBL4308646 | 0.83 | AXL (0.48) | AXLKDRINSRNPC1PKM | |
| SCHEMBL930647 | 0.83 | AXL (0.57) | AXLKDRINSRNPC1PKM | |
| SCHEMBL929400 | 0.83 | AXL (0.47) | AXLKDRINSRNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-2074115-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008083354-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2484679-B1 | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-8796259-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2484679-A2 | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KDR 88/4885INSR 143/4885 |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885KDR 88/4885INSR 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.